Protein interaction analysis of senataxin and the ALS4 L389S mutant yields insights into senataxin post-translational modification and uncovers mutant-specific binding with a brain cytoplasmic RNA-encoded peptide by Bennett, Craig L. et al.
Protein Interaction Analysis of Senataxin and the ALS4
L389S Mutant Yields Insights into Senataxin Post-
Translational Modification and Uncovers Mutant-Specific
Binding with a Brain Cytoplasmic RNA-Encoded Peptide
Craig L. Bennett1,2*, Yingzhang Chen3, Marissa Vignali4, Russell S. Lo4, Amanda G. Mason2, Asli Unal2,
Nabiha P. Huq Saifee5, Stanley Fields4, Albert R. La Spada2,6,7,8
1Comparative Genomics Centre, School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland, Australia, 2Department of Pediatrics,
University of California San Diego, La Jolla, California, United States of America, 3Department of Pediatrics, University of Washington Medical Center, Seattle, Washington,
United States of America, 4Department of Genome Sciences, University of Washington Medical Center, Seattle, Washington, United States of America, 5Department of
Pharmacology, University of Washington Medical Center, Seattle, Washington, United States of America, 6Department of Cellular & Molecular Medicine, University of
California San Diego, La Jolla, California, United States of America, 7Department of Neurosciences, University of California San Diego, La Jolla, California, United States of
America, 8 Rady Children’s Hospital, La Jolla, California, United States of America
Abstract
Senataxin is a large 303 kDa protein linked to neuron survival, as recessive mutations cause Ataxia with Oculomotor Apraxia
type 2 (AOA2), and dominant mutations cause amyotrophic lateral sclerosis type 4 (ALS4). Senataxin contains an amino-
terminal protein-interaction domain and a carboxy-terminal DNA/RNA helicase domain. In this study, we focused upon the
common ALS4 mutation, L389S, by performing yeast two-hybrid screens of a human brain expression library with control
senataxin or L389S senataxin as bait. Interacting clones identified from the two screens were collated, and redundant hits
and false positives subtracted to yield a set of 13 protein interactors. Among these hits, we discovered a highly specific and
reproducible interaction of L389S senataxin with a peptide encoded by the antisense sequence of a brain-specific non-
coding RNA, known as BCYRN1. We further found that L389S senataxin interacts with other proteins containing regions of
conserved homology with the BCYRN1 reverse complement-encoded peptide, suggesting that such aberrant protein
interactions may contribute to L389S ALS4 disease pathogenesis. As the yeast two-hybrid screen also demonstrated
senataxin self-association, we confirmed senataxin dimerization via its amino-terminal binding domain and determined that
the L389S mutation does not abrogate senataxin self-association. Finally, based upon detection of interactions between
senataxin and ubiquitin–SUMO pathway modification enzymes, we examined senataxin for the presence of ubiquitin and
SUMO monomers, and observed this post-translational modification. Our senataxin protein interaction study reveals a
number of features of senataxin biology that shed light on senataxin normal function and likely on senataxin molecular
pathology in ALS4.
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Introduction
Senataxin is a large 303 kDa protein so named to signify its
homology with the yeast protein Sen1p. Senataxin is a nuclear
protein, and it contains a highly conserved DNA/RNA super-
family-1 helicase domain, indicative of its role in nucleic acid
processing. Disease-associated mutations in the senataxin gene
(SETX) fall into two distinct categories. Recessive mutations cause
a severe form of ataxia, Spinocerebellar Ataxia Autosomal
Recessive 1 (SCAR1– OMIM: 606002), which is also known as
Ataxia with Oculomotor Apraxia 2 (AOA2); while dominant
mutations cause a motor neuron disease known as amyotrophic
lateral sclerosis type 4 (ALS4; OMIM: 608465) [1,2]. As two
distinct neurodegenerative conditions result from SETX mutations,
senataxin is likely important for neuron survival [1,3,4].
ALS4 is an unusual familial form of ALS, with presumed disease
penetrance of 100%. Age of disease onset varies widely, ranging
from 5–63 years in the largest pedigree examined to date [2].
Pathologically, post-mortem examination has revealed atrophic
spinal cords with marked loss of anterior horn cells and
degeneration of corticospinal tracts, with an absence of sensory
clinical signs or symptoms [2]. ALS4 patients were originally
studied electrophysiologically, and noted to display hyperactive
deep tendon reflexes and normal sensory function [2,5]. Motor
conduction studies revealed reduced evoked amplitudes and
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normal conduction velocity. Overall, the clinical picture indicates
an essentially pure motor systems disorder typical of ALS.
Altered RNA processing is a known cause of neurodegenera-
tion, as documented in spinal muscular atrophy (SMA) [6], and
the fragile X syndrome of mental retardation [7]. The theme of
altered RNA processing in motor neuron disease has been further
emphasized by the recent discovery of roles for the RNA binding
proteins TDP-43 (ALS10) [8,9] and FUS (ALS6) [10,11] in
sporadic and familial ALS. Based on the strong conservation of the
senataxin helicase domain, aberrant RNA processing is also likely
to be a feature of ALS4 neurodegeneration. While the precise
functions of senataxin are yet to emerge [12–18], senataxin
mutations known to cause ALS4 are limited to three amino acid
substitutions. In one very large ALS4 pedigree, we discovered that
all 49 affected members carried a L389S substitution mutation [1].
Yet, while two other rare mutations were reported in other
senataxin protein domains (R2136H and T3I) [1], the L389S
mutation has emerged as the most common cause of ALS4 thus far
[19,20].
The L389S mutation resides in the middle of a domain with
functional importance for both senataxin and yeast Sen1p [21,22].
Interestingly, missense mutations, associated with both dominant
ALS4 and recessive SCAR1/AOA2, are located in either the
helicase domain or the amino-terminal protein-interaction domain
[4]. In yeast, the amino-terminal domain is defined by amino acids
1–600, and is the minimal fragment required to interact with key
proteins, including Rad2p, a deoxyribonuclease required in DNA
repair; Rnt1p (RNase III), an endoribonuclease required for RNA
maturation; but most prominently with Rpo21p (Rpb1p), a
subunit of RNA polymerase II (RNAP II) [22]. Interaction of
sen1p/senataxin with RNAP II is presumed essential to facilitate
their critical role in transcription termination and to resolve
transient RNAP II mediated R-loop structures via the conserved
helicase domain [14,15]. Given the high level of structural
conservation between Sen1p and senataxin [3] [4,23], and the
fact that Sen1p can bind functionally important proteins via its
amino-terminal domain, we used the first 650 residues of the
senataxin protein to screen a human brain expression library by
yeast two-hybrid (Y2H) analysis, and compared the results for wild
type senataxin and L389S senataxin. Our results revealed key
aspects of senataxin biology and yielded an unexpected interaction
that may have relevance to ALS4 disease pathogenesis.
Materials and Methods
Human Brain cDNA Expression Library: Y2H Screen
We wanted to compare proteins found to interact with wild type
senataxin, with those interacting selectively with the L389S mutant
form of the protein. To achieve this, we screened a human brain
expression library (Clontech) produced from cDNA sequences
isolated from the brains of three Caucasian patients aged 41–61
years, and subsequently cloned into the activation domain of
pGADT7-Rec vector by homologous recombination.
Using the Matchmaker GAL4-based system, two independent
Y2H screens were undertaken: (i) screen 1 utilized wild type
senataxin residues 1–650; and (ii) screen 2 utilized the same
fragment but containing the L389S mutation. Both senataxin bait
fragments were cloned into the binding domain vector, pGBKT7-
BD. The wt and L389S mutant bait constructs were cloned from
full-length cDNA expression constructs generated previously [3].
Y2H controls included: (i) determining that BD-SETX-wt and BD-
SETX-L389S expression were not toxic to yeast; (ii) testing for
non-specific auto-activation of reporter genes; (iii) non-interactor
negative controls, pGBKT7-53 and pGADT7-Lamin; and (iv)
positive control interactors, pGADT7-T and pGBKT7-53. These
screens were performed using a mating strategy with the library
pre-transformed into host strain Y187 [24,25].
Selected clones thought to result from valid prey-clone
interaction with senataxin (BD-SETX) were further tested in two
ways: (i) the mating was retested with the putative interacting
clones pre-transformed into the PJ69-4A strain; and (ii) the library
clone was isolated and co-transformed with senataxin bait vector
in a patch-selection/serial dilution strategy. The ‘patching’
strategy is based on first selecting the co-transformants on
Leu2/Trp- media. Then, single colonies were used to inoculate
an overnight (O/N) culture, and from this we ‘patched’ four, 5-
fold serial dilutions beginning with the stock O/N growth onto
Leu2/Trp2/His- selective media with 3 mM 3-AT. In addition to
the wild type and L389S bait clones, we generated a third bait
clone, the AOA2 mutant, W305C. We surmised this clone may
represent a loss-of-function mutant form of senataxin protein.
Blastn Analysis of Y2H Clone Containing BCYRN1
(NR_001568.1) Sequence
We took the DNA sequence from this ALS4 interacting Y2H
clone and subjected it to alignment analysis. The 138 bp of DNA
sequence is shown here: gat cta gag gcc gag gcg gcc gac atg ttt ttt
ttt ttt ttt tcc ttt ttc tgg aga acg ggg tct cgc tat att gcc cag gca ggt ctc
gaa ctc ctg ggc tca agc tat cct ccc gcc tct tag cct ccc tga gag.
This sequence was submitted to NCBI database search analysis:
Name - nr; Description - Nucleotide Collection nt; Program -
BLASTN 2.2.28. While the top alignment hit overall was Pan
paniscus (Bonobo) ncRNA BC200 (AF067778.1), the top human
hit was BCYRN1 (NR_001568.1). We then undertook a direct
alignment using NCBI Blastn between the 138 bp clone sequence
and human ncRNA BCYRN1. The portion of this clone encoding
a peptide with homology to known primate proteins is translated
here: ggg tct cgc tat att gcc cag gca ggt ctc gaa ctc ctg ggc tca agc
tat cct ccc gcc tct R GSRYIAQAGLELLGSSYPPAS.
SETX Expression Constructs
Expression constructs were based on PCR amplifying the
amino-terminal SETX 1–650 aa’s (n-Senataxin) from our existing
full-length SETX wt and L389S vectors [3]. We ruled out the
possibility of using the original full-length expression constructs for
these studies as they produce extremely low expression levels, even
when using the Amaxa nucleofection transfection method [3]. In
brief, PCR amplification utilized the following primers: forward
primer, 59-GGT ACC cca cca tgg att aca agg atg acg-39 (Kpn1
site) and reverse primer 59 GAA TTC cat tgg ttc ttt aga aaa tgt tgg
gct g - 39 (EcoR1 site). Flag epitope was already present in the
template plasmid. We cloned first into the pCRHII-TOPO holding
vector. Then by standard cloning, we directed the flag-tagged, n-
Senataxin into the final expression vector, pcDNA3.1, and
validated the coding sequences by DNA sequence analysis. For
the GST-tagged senataxin expression construct we utilized the
pGEX-4T-2 vector (GE, Life Sciences).
Cell Culture, Transfection, Immunoprecipitation and
Western Blot
HEK293 cells were obtained from the ATCC and cultured in
DMEM media supplemented with 10% fetal bovine serum (FBS)
at 37uC. Transfection of 293T cells was performed using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol in 6-well culture dishes.
24 hours post-transfection, cells were washed with room
temperature (R/T) PBS and a second wash with PBS at 4uC.
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After gently removing the PBS wash, cells were lysed with 600 ml
of RIPA buffer for 30 min at 4uC. A cell scraper was used to
ensure efficient lysis. Lysates were syringed with a 26-gauge needle
and spun at 10,000 rpm for 10 min at 4uC. 60 ml of each sample
was collected as a control (Total Cell Lysate). In preparation for
the anti-GFP immunoprecipitation (IP), we performed a pre-clear
with protein A/G agarose magnetic beads to remove proteins
binding non-specifically to beads. In brief, we washed 10 ml of 1:1
ratio protein A/G beads with 1 ml RIPA, three times. Beads were
resuspended in 10 ml RIPA per sample and then added to each
sample, which was rotated for 30 min at 4uC. Supernatant was
removed to a new tube by binding A/G beads to the magnetic
column. Then to begin the anti-GFP binding, we added 5 ml
suspension of anti-GFP antibody (magnetic beads) (ab69315).
Samples were rotated O/N at 4uC. Unbound supernatant was
removed by washing 3-times with 500 ml RIPA buffer at 4uC.
Prior to gel electrophoresis protein separation, we added 100 ml of
SDS loading buffer to beads and boiled for 10 min at 80uC. After
removal of magnetic beads, IP-samples were further analysed by
Western blot (WB).
Protein lysates were resolved using NuPAGEH Tris-Acetate
gradient Gels (Invitrogen) and transferred to PVDF membrane
(Sigma) by 1 hr of electroblot at 30 volts and blocked with 4%
non-fat dry milk. To detect FLAG epitope, anti-FLAG M2
antibody (Sigma: F1804) was used (1:5,000) in conjunction with
anti-mouse HRP secondary antibodies (Sigma: A9044) (1:10,000).
The ECL Plus HRP detection kit (Amersham) was used for
chemiluminescent detection. The use of 20 mM N-Ethylmalei-
mide (Sigma-Aldrich) was used to inhibit ubiquitinase and
sumoylase enzyme activity.
Results
Senataxin Amino-terminal Protein Interactions Identified
by Y2H Analysis
We prepared wild type senataxin as bait (DB-SETX-wt) and
L389S senataxin as bait (DB-SETX-L389S), and proceeded to
screen a human brain cDNA prey library. This Y2H analysis
yielded 27 interacting clones for DB-SETX-wt and 57 interacting
clones for DB-SETX-L389S in the initial two screens. Sequence
analysis of the resultant clones revealed 18 unique transcripts,
which were then re-tested (Fig. 1). Five false-positives were
excluded from further analysis, as these clones also interacted with
the negative control prey (pGADT7-Lamin), or interactions were
not reproducible on re-testing. Most of the interacting library
clones were full-length or nearly full-length, suggesting the library
was of high quality. We categorized the 13 remaining validated
clones into five groups (Table 1), as follows, based upon putative
function.
Senataxin self-interaction (Group 1). We designated this
group for senataxin self-interaction or dimerization. Both wild-
type and L389S baits pulled out single, large independent clones
from the initial library screens, which were subsequently validated
by a range of assays (see below).
Ubiquitin/SUMO modifiers (Group 2). We identified five
interactors, each representing proteins in either the Ubiquitin
protein degradation pathway or the related SUMO cascade, a
moiety often used for protein trafficking [26]. Examples include
SAE2, which is the E1-activating enzyme subunit 2 in the
sumoylation pathway. SUMO is the small ubiquitin-like modifier
added to the target protein and UBC is the human poly-ubiquitin
protein. Interestingly, in addition to these Group 2 proteins with
overt sumoylation functions, TDG (Group 3), TOPORS (Group
3), and HIPK2 (Group 4) have also been implicated in
sumoylation pathway regulation – in addition to their defined
primary functions.
DNA/RNA binding proteins (Group 3). We observed a
unique group of four DNA/RNA binding proteins involved in
RNA surveillance, DNA repair, and other helicase functions. The
EXOSC9 protein (exosome component 9) is part of the exosome,
a multi-protein complex capable of degrading various types of
RNAs. This 39 to 59 exo-ribonuclease complex is required for 39
processing of 7S pre-rRNA to mature 5.8S rRNA that is localized
to the nucleolus [27]. Thymine DNA glycosylase (TDG) fulfills the
essential role of correcting G/T mismatches by a mismatch-
specific DNA-binding glycosylase activity, thereby linking tran-
scription and DNA repair [28]. TDG also exhibits sumoylation
pathway function, as the SUMO binding activity of TDG is
required prior to its covalent SUMO modification and subsequent
colocalization with the promyelocytic leukemia protein (PML)
within PML-containing nuclear bodies [29]. CHD3, the chromo-
domain helicase DNA-binding protein 3, is a central component of
the nucleosome remodeling and histone deacetylase repressive
complex (NuRD), and it has two chromatin organization domains
(i.e. chromo-domains) and a helicase domain [30]. Topoisomerase
I-Binding Arginine/Serine-Rich Protein (TOPORS) may perform
a variety of complex functions, and TOPORS mutations cause
autosomal dominant Retinitis Pigmentosa with perivascular retinal
pigment epithelium atrophy [31]. TOPORS is also known as p53-
binding protein 3 [32], and acts as a SUMO E3 ligase for p53
[33], in addition to serving as a binding partner for both SUMO-1
and SUMO-2 [34].
Kinase regulator (Group 4). We identified a single protein
known as the homeodomain interacting protein-kinase 2 (HIPK2).
HIPK2 co-localizes and interacts with p53 and CREB-binding
protein within PML nuclear bodies [35]. Interestingly, HIPK2
nuclear localization and function is mediated by a SUMO
interaction motif [36], further underscoring the extent of
sumoylation pathway interactome relationships existing among
senataxin interactors identified in this Y2H screen. Activation of
HIPK2 by UV-radiation leads to selective p53 phosphorylation,
facilitating CBP-mediated acetylation of p53 and promotion of
p53-dependent gene expression [35].
ALS4 specific interaction (Group 5). We noted a unique
and highly reproducible protein interaction specific to only L389S
senataxin. The interacting clone contained KIF1B cDNA
sequence, initially suggesting that it was KIF1B, a kinesin
molecular motor protein previously mutated in a pedigree with
neurological disease [37]. However, further DNA sequence
analysis revealed that this clone consists of two cDNA fragments,
likely fused during cDNA library construction. Specifically, this
clone contains the major portion of Brain cytoplasmic RNA 1,
BCYRN1 (NR_001568), fused to a KIF1B cDNA fragment
containing intron 5, exons 6–9, and ,1.4 kb of intron 9. This
interaction was not observed with the AOA2 mutant, DB-SETX-
W305C, when used as bait.
Senataxin Self-association is not Abrogated by the L389S
Mutation
ALS is one of a number of neurodegenerative proteinopathies in
which protein aggregation may play a role in disease pathogenesis.
As SOD1 aggregation in ALS1 may stem from impaired
dimerization [38], we chose to examine the effect of senataxin
mutation on its dimerization properties. To address this issue, we
expressed GST-tagged senataxin (1–600) in E. coli, and after in vitro
cleavage, we examined recombinantly produced amino-terminal
senataxin by size-exclusion chromatography. Coomasie staining
revealed the expected ,70 kDa band for senataxin (1–600)
ALS4 Senataxin Protein Interaction Analysis
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(Fig. 2A, insert), while size-exclusion chromatography revealed a
strong elution peak at ,140 kDa (Fig. 2A), consistent with dimer
formation. An initial smaller peak corresponding to a higher
molecular mass was also noted, and may represent aggregated
protein (Fig. 2A). To directly evaluate senataxin self-association,
we cloned the amino-terminal senataxin cDNA (both –wt and –
L389S) into the CheckMate mammalian two-hybrid (M2H)
expression system (Promega). M2H analysis revealed strong
interaction signals for SETX-wt homodimer, SETX-L389S homo-
dimer, and SETX-wt – SETX-L389S heterodimer, though the
self-association interaction appeared greatest for SETX-wt homo-
dimer (Fig. 2B). To confirm these findings, we performed cross-
linking studies using FLAG-tagged amino-terminal senataxin-wt
and amino-terminal senataxin-L389S expression constructs in
HeLa cells treated with disuccinimidyl suberate. Untreated HeLa
cells expressing either SETX-wt or SETX-L389S displayed an
intense band at ,75 kDa on Western blot analysis, corresponding
to senataxin monomer, as expected (Fig. 2C). When we
immunoblotted transfected cells treated with the cross-linking
agent, disuccinimidyl suberate, we observed two bands both
Figure 1. Validation tests of senataxin interactors identified from a human brain expression library. In (A) that follow, the four pGBKT7-
BD bait vectors (BD-SETX-wt, BD-SETX-L389S, BD-SETX-W305C and BD-p53) were used in array with each pGADT7-AD test library prey clone: (i),
senataxin; (ii), SAE2 (ubiquitin E1); (iii), Sumo; (iv), UBC and (v), KIF1B. Overnight cultures were plated 5-fold serial dilutions right to left (hatched
triangle below). In (B), the library clone containing KIF1B and BCYRN1-rc cDNA sequences were sub-cloned to test which fragments were required for
interaction as bait with: (i) the KIF1B coding exons 6–9; (ii) the 138bp of BCYRN1-rc; and (iii) the original full-length, ‘hybrid-clone’ was used as a
positive control. The BCYRN1-rc sequence was sufficient to interact with N-terminal L389S senataxin. A 4-fold serial dilution (from right to left –
hatched triangle) was undertaken for wt-SETX and L389S-SETX bait clones with each of the three prey fusion clones.
doi:10.1371/journal.pone.0078837.g001
Table 1. Y2H analysis for wt and L389S senataxin (1–650).
No Group Name Function NCBI ref wt L389S W305C Amino acids*
1 1 SETX DNA/RNA helicase NM_015046 +1 +1 + 1–668 N-term
2 2 SAE2 SUMO-1 activating enzyme subunit 2 NM_005499 +2 +3 + 451–641 ter
3 2 Ubc9 Ubiquitin-conjugating enzyme E2I NM_003345 +11 +31 + 1–159 tot
4 2 PIAS E3 SUMO-protein ligase NM_016166 +1 +3 + 318–652 ter
5 2 Sumo{ Small ubiquitin-like modifier NM_003352 +2 +4 + 1–102 tot
6 2 UBC Ubiquitin C - gene encoding 9 repeats NM_021009 +2 +2 + 1–532 tot
7 3 EXOSC9 Exosome component 9 NM_005033 +2 +3 + 158–440 ter
8 3 TDG G/T mismatch- thymine DNA glycosylase NM_003211 +2 +3 + 74–411 ter
9 3 CHD3 Chromodomain helicase DNA BP-3 NM_005852 +1 +1 + 1818–1967
10 3 TOPORS Topoisomerase I binding NM_005802 +2 +3 + 468–1046 ter
11 4 HIPK2 Homeodomain interacting protein-kinase2 NM_022740 +1 +2 + 216–527
12 5 KIF1B Kinesin, anterograde transport NM_015074 20 +1 2 out of frame
13 5 BCYRN1 Homo sapiens brain cytoplasmic RNA 1 NR_001568 20 +1 2 antisense
*Amino acids regions encoded by the representative clones are given for the wild type or mutant interacting clones that were used for subsequent validation retesting:
ter = terminus; tot = total protein; and antisense indicates that the BCYRN1 clone fragment was present in the 39 to 59 orientation. The number of independent clones
obtained from the original wt and mutant library screens are listed as superscript numbers to the+in the ‘wt’ and ‘L389S’ columns, respectively. The SUMO clones
(NM_003352) were isoform a, variant transcript 1 ({).
doi:10.1371/journal.pone.0078837.t001
ALS4 Senataxin Protein Interaction Analysis
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e78837
migrating at .300 kDa for SETX-wt and SETX-L389S-expressing
HeLa cells, without any senataxin monomer band present
(Fig. 2C). The production of senataxin multimers by both
SETX-wt and SETX-L389S confirmed that the L389S mutation
does not prevent senataxin self-association.
Senataxin is Subject to Ubiquitin – SUMO Post-
translational Modification
The Y2H screen identified five interacting proteins that
promote ubiquitination or SUMOylation (group 2), suggesting
that senataxin is regulated by one or both of these pathways.
Indeed, many redundant hits from both initial screens with wild-
type senataxin and L389S senataxin were from this group.
Previous studies with yeast Sen1p have documented that the
amino-terminal region of Sen1p contains domains required for
Sen1p degradation by the ubiquitin-proteasome system [39].
Although the basis of senataxin protein turnover is ill-defined,
another possible role for ubiquitination and sumoylation is
regulatory post-translational modification. To determine if sena-
taxin is subject to such post-translational modification, we
transfected FLAG-tagged senataxin-expression constructs into
HEK293 cells, and then prepared cell extracts in the presence of
NEM to inhibit ubiquitin and SUMO cleavage. We then
performed Western blot analysis and noted a ,7 kDa shift
upward for all FLAG-SETX-wt protein isolated from NEM-
treated HEK293 cell extracts (Fig. 3). A similar gel shift was
observed with analysis of extracts from cells transfected with the
FLAG-SETX-L389S construct suggesting the mutation does not
affect this modification. Given the limitation of protein size
estimates based on migration rates alone, this size increase is
potentially consistent with the addition of a single ubiquitin or
SUMO monomer.
Figure 2. Biochemical assays showing that amino-terminal senataxin (1–650) seldom exists as a monomer, but is stable as a dimer.
(A) Polyacrylamide gel electrophoresis was used to resolve purified senataxin peptide at,70 kDa, visualized by Coomasie stain. The filtration elution
predicts a fragment size of , 140-kD suggesting that the predominant form of purified senataxin exists as a dimmer. (B) Average luciferase activity
(luminosity) for three transfection experiments. Column 1, pBIND/pACT (negative control); column 2, Id/MyoD (positive control); column 3, homo-wt
[pBIND-SETX (1–650 wt) with pACT-SETX (1–650 wt)]; column 4, homo-L389S [pBIND-SETX (1–650 L389S) with pACT-SETX (1–650 L389S)]; and
column 5, hetero [pBIND-SETX (1–650 wt) with pACT-SETX (1–650 L389S)]. (C) HeLa cells were transfected with Flag-tagged wt-SETX and L389S-SETX
expression constructs. Compared with untreated HeLa cells (U), treatment with cross-linking (CL) reagent (DSS) caused 75 kDa bands to shift to
greater than 300 kD with almost no monomer remaining.
doi:10.1371/journal.pone.0078837.g002
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L389S-senataxin Binds to a Unique Peptide Encoded by
BCYRN1-reverse Complement
Closer inspection of the fused BCYRN1-KIF1B clone revealed
that the BCYRN1 portion is oriented in the reverse complement
direction (BCYRN1-rc) relative to the Gal4 activation domain, and
DNA sequencing confirmed a stop codon immediately prior to the
KIF1B cDNA sequence (Fig. 4A), ruling out expression of this
gene product. We then separately subcloned BCYRN1-rc and
KIF1B coding exons 6–9 into the pGADT7-Rec vector (Fig. 4A),
and retested the L389S-senataxin bait construct for an interaction
with these two subclones by Y2H analysis. We found that
interaction with ALS4 L389S senataxin was dependent on
BCYRN1-rc, but not on KIF1B coding sequence (Fig. 4B), a result
that we robustly reproduced on repeated trials. A previous study
identified BCYRN1 as a non-coding RNA (ncRNA) gene that
yields an ,200 bp RNA, representing a primate neural-specific
RNA polymerase III transcript [40]. BCYRN1 (NR_001568.1)
spans ,80 kb on chromosome Xq13.1, and is transcribed across
11 X-linked genes including the CMT1X (OMIM: 302800)
peripheral neuropathy related gene, Connexin 32. Two related
brain cytoplasmic RNAs, BC1 and BCYRN1 (also known as
BC200) have been shown to modulate gene expression at the level
of protein translation [41–44]. This RNA class may represent a
recently evolved transcript type predicted to regulate protein
synthesis. BCYRN1 derives from a transcribed monomeric Alu
element which appears to have transposed from the signal
recognition particle (SRP) RNA, and in particular from the SRP
RNA region involved in translation arrest [45]. Although this
regulatory RNA class is very novel and therefore remains
uncharacterized, in normal aging, cortical BCYRN1 levels typically
decline and are reduced by .60% after age 48, but in Alzheimer’s
disease brains, BCYRN1 levels have been documented to increase
[40].
Following our NCBI Blastn analysis (Fig. 4C–D), our
identification of a peptide product from the BCYRN1-rc sequence
led us to consider the hypothesis that this translational product is
genuine and not simply an artefact. One approach to evaluate the
veracity of the BCYRN1-rc translational product is to scan the
proteome for homologous proteins containing this domain. When
we BLASTed the BCYRN1-rc peptide sequence against the NCBI
non-redundant protein sequence database, we identified a 21
amino acid region GSRYIAQAGLELLGSSYPPAS, within the
BCYRN1-rc coding sequence (Fig. 4C), that yielded highly
significant hits for a large number of proteins, all restricted to
the proteomes of primates. For humans, we found two proteins
with significant homology: Palmitoyl-protein thioesterase 1 (PPT1)
(NM_000310) and C14orf178 (NM_174943). The level of identity
between the BCYRN1-rc peptide and the PPT1 protein was 81%,
while the level of identity with the C14orf178 protein was slightly
higher at 86%. PPT1 protein is a small glycoprotein involved in
the catabolism of lipid-modified proteins during lysosomal
degradation, and mutations in the PPT1 gene cause infantile
neuronal ceroid lipofuscinosis 1 (CLN1; OMIM #256730) and
neuronal ceroid lipofuscinosis 4 (CLN4; OMIM #204300). The
C14orf178 gene encodes two small proteins of 92 amino acids and
122 amino acids, based upon its two predicted RNA isoforms
(Fig. 5A). Both predicted proteins are homologous to the
BCYRN1-rc peptide (Fig. 5B–C). The C14orf178 gene consists
of 3 exons, spanning ,9 kb of genomic sequence (NCBI UniGene
Hs. 375834). Although the C14orf178 gene encodes two protein
products, their functions remain unknown. Interestingly, the
C14orf178 protein contains a 32 amino acid domain with 61%
homology to the heterogeneous nuclear ribonucleoprotein U-like 1
protein (HNRNPUL1) (Fig. 5D).
L389S-senataxin Interacts with the C14orf178 Protein
Product in HEK293 Cells
To determine if L389S-senataxin would interact with human
proteins containing sequence similar to the BCYRN1-rc peptide, we
obtained a C14orf178 GFP-tagged isoform1 expression construct.
After we cloned the amino-terminal senataxin (both -wt and -
L389S) into a mammalian expression construct, with the inclusion
of a FLAG tag, we co-transfected senataxin-wt or senataxin-L389S
with C14orf178-GFP. Western blot analysis confirmed expression
of Flag-tagged recombinant senataxin protein. When we immu-
noprecipitated the C14orf178 expression product with an anti-
GFP antibody, we found that Flag-tagged senataxin containing the
L389S mutation is pulled down by C14orf178-GFP, but wild-type
senataxin is not pulled down by C14orf178-GFP (Fig. 6). When
we immunostained co-transfected HEK293 cells, we noted that
both FLAG-L389S-senataxin and C14orf178-GFP localize to the
nucleus (data not shown).
Discussion
We have attempted to shed light on the senataxin protein to
understand which of its functions are critical to neuron survival.
Despite the obvious link with nucleic acid processing indicated by
the presence of a conserved DNA/RNA helicase, the nature of
senataxin loss-of-function responsible for AOA2 neurodegenera-
tion remains unknown. Similarly, the molecular basis of senataxin
gain-of-function neurotoxicity in ALS4 also remains enigmatic. To
remedy this, we pursued an unbiased analysis of the senataxin
interactome using a yeast two-hybrid approach, and performed a
protein interaction screen with both wild-type senataxin protein
and L389S senataxin as the most common ALS4 mutation. Our
results revealed several unknown aspects of senataxin biology.
First, evidence in support of senataxin dimerization was obtained.
Direct analysis of self-association by mammalian two-hybrid
(M2H) interaction experiments and by disuccinimidyl suberate
cross-linking confirmed senataxin self-association. The L389S
mutation did not block dimer formation, but a reduced preference
for this state is suggested by the more sensitive M2H analysis.
It is important to emphasize that the ALS4 L389S substitution
and all AOA2 missense mutations within senataxin’s amino-
terminal protein interaction domain occur at residues that are
100% conserved in all vertebrate species from zebrafish
(XP_690945) to man. Indeed, Sen1p protein levels are tightly
regulated by a post-transcriptional mechanism requiring the
amino-terminal domain [39]. While similar regulation at the
protein level has not been shown for mammalian senataxin, high-
level protein expression of only truncated senataxin fragments, but
not full-length senataxin, can be achieved in mammalian cells [3].
Figure 3. HEK293 cells are transfected with 1.5 mg (lanes 1, 2),
1.0 mg (lanes 2, 3) and 0.5 mg (lanes 5, 6) of Flag-wt-SETX. Note
that in lanes, 2, 4, and 6 the transfected cells were treated with N-
ethylmaleimide (NEM) to prevent the cleavage of either SUMO or
ubiquitin and a band shift of,7 kDa is observed, suggesting that this is
likely a sumoylation event.
doi:10.1371/journal.pone.0078837.g003
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Figure 4. Structure of the brain cDNA library clone showing specific interaction with ALS4 L389S amino-terminal senataxin. Here we
see a diagram of the fusion clone of BCYRN1 reverse complement (BCYRN1-rc) and KIF1B cDNA sequences, with subclones of BCYRN1-rc and KIF1B
coding exons 6–9 shown above the clone map (A), and relative length of relevant clone sequence in base pairs (B). Below is shown the minimal open
reading frame peptide product capable of binding L389S senataxin, contained within the BCYRN1 sequence (C). The unique protein fragment
highlighted in red text has near perfect homology with several human proteins with brain specific expression. When aligned by NCBI Blast, the
138 bp clone sequence (Query) shows 99% identity with BCYRN1 trancsript NR_001568.1 (Sbjct) over a 110 bp stretch (D).
doi:10.1371/journal.pone.0078837.g004
Figure 5. The 21 amino acid sequence which is translated from BCYRN1-rc (fragment-21) showed strong homology to two human
proteins PPt1 and C14orf178. (A) The gene sequence of C14orf178, in which both isoforms contain fragment-21. (B) The larger protein encoded
by C14orf178 isoform1. (C) The alignment of the BCYRN1-rc fragment with C14orf178. (D) The region of homology that C14orf178 isoform2 shares
with the hNRNPUL-1 protein.
doi:10.1371/journal.pone.0078837.g005
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As post-transcriptional regulation of Sen1p involves the ubiquitin
proteasome system, our discovery of an interaction between
mammalian senataxin and ubiquitination - SUMOylation path-
way factors suggests that regulation by this pathway may be
conserved between yeast and mammals. We confirmed the
functional significance of these putative interactions when we
found that NEM treatment of protein extracts (to prevent sumo/
ubiquitin cleavage) yielded an ,7 kDa shift in the molecular mass
of senataxin. Although an ,7 kDa shift is smaller than expected
for a single SUMO or ubiquitin addition and could instead
represent phosphorylation, the complete elimination of the
modification upon NEM treatment makes sumoylation or
ubiquitination most likely, as the small shift could represent the
migration characteristics of modified senataxin protein. Future
study into the nature of senataxin post-translational modification is
clearly needed to define the type and number of senataxin post-
translational modifications. Bioinformatics analysis indicates that
AOA2 or ALS4 point mutations in senataxin do not coincide with
predicted sites of ubiquitination or sumoylation; nonetheless, a
mono-ubiquitination or sumoylation modification could be
important for understanding senataxin normal function, involving
processes such as subcellular localization [26].
The DNA/RNA processing proteins (group 3) and homeodo-
main interacting protein-kinase 2 (group 4) interactors identified
by the screen also provide important clues to the normal function
of senataxin. Interestingly, the W305C AOA2 loss-of-function
mutant, used in the post Y2H screen analysis was also able to bind
all 13 wild type senataxin protein interactors. The significance of
this is unclear, but one possible explanation is that AOA2 missense
SETX mutations may yield unstable, reduced protein levels in
mammalian cells, a hypothesis that remains untested due to the
absence of reliable senataxin Ab’s. Nonetheless, lack of interaction
between W305C senataxin and BCYRN1-rc indicates the
interaction between L389S senataxin and BCYRN1-rc is specific,
and may represent the type gain-of-function interaction expected
from a dominant SETX mutation. BCYRN1 is part of the brain
cytoplasmic RNA class and shows a number of unique features: (i)
it is found only in primates [40]; (ii) it is specifically expressed in
neurons and transported to postsynaptic dendrites [46]; (iii) it is
derived from a signal recognition particle RNA involved in
translation arrest [41–44]; (iv) it interacts with poly(A)-binding
protein a regulator of translation initiation [47]; and (v) it is found
to interact with FMRP, binding with several FMRP mRNA
targets via direct base-pairing [48]. Data mining with the
BCYRN1-rc translation product revealed strong homology to
several proteins, including PPT1 and C14orf178. Further exper-
iments indicated that L389S-senataxin can specifically interact
with C14orf178 in mammalian cells, while wild-type senataxin did
not. Although further studies are needed to determine if
differential senataxin binding to the C14orf178 protein product
is relevant to ALS4 disease pathogenesis, evidence of this
interaction indicates that the L389S mutation may promote
disease pathology by aberrant binding to normally off-target
proteins. BCYRN1 is divided into three domains: (i) a 59 portion
homologous to the Alu Lm (Left Monomer); (ii) a central
adenosine-rich region; and (iii) a terminal 43-nt non-repetitive
domain [49]. The Alu Lm portion has homology to the Alu repeat
element common in the primate genome, and contains the
sequence that in reverse complement encodes the 21 amino acid
peptide which ALS4 L389S senataxin binds. Alu sequences will
inevitably be present in the reverse orientation ,50% of the time.
Given the growing awareness of complex human RNA transcrip-
tion and multiple regulatory RNA mechanisms [50,51], it is highly
possible that peptide sequences similar to that isolated from our
comparative Y2H screen could be generated, even if their
translation was unintended. For example, a new toxic mechanism
is gaining acceptance as the cause of sporadic and familial ALS
based on C9orf72 hexanucleotide repeat expansions. It has been
found that non ATG-mediated translation occurs when the
GGGGCC expansion within the normally untranslated intron
exceeds a certain limit, thereby generating toxic poly-(Gly-Ala)
peptides [52,53]. Further studies are required to explore this
potentially toxic mechanism that we suggest may occur in ALS4
patients based on aberrant L389S senataxin interactions.
This study has uncovered new avenues of research for senataxin
biology and ALS4/AOA2 associated mutations. But undoubtedly,
many questions remain unanswered. For example, why did a
protein such as C14orf178 not emerge during our Y2H screen?
One answer is that C14orf178 may not be highly expressed in
brain, and based on our analysis of UniGene clusters, C14orf178
was only expressed in rare cancer derived cDNA clones. Yet there
are examples that reversed Alu derived sequences find their way
into the human transcriptome. The PPT1 isoform identified by the
Wellcome Trust Sanger Institute, 13-JAN-2009 (CAI11026, 2009),
has an 87 bp alternate exon 2 which encodes a near perfect match
to our ALS4 interacting fragment with the addition of just eight
amino acids. Nevertheless, any mechanism put forward to
potentially address the ALS4 neuronopathy should provide
flexibility to account for the highly variable age of disease onset.
If ALS4 senataxin were to retain most normal functions (as in our
study it also bound all the same interactors as wild type senataxin),
but through point mutation gained the ability to bind ‘abnormally
generated’ proteins; this would be an example of the type of model
flexibility needed to account for the broad range of disease onset
associated with the L389S substitution in ALS4 patients.
Figure 6. HEK293 cells transfected with expression constructs
of Flag-wt-SETX (F-wt); Flag-L389S-SETX (F-L389S); and
C14orf178-GFP (C14orf178). In the upper panel, proteins isolated
upon GFP immunoprecipitation were immunoblotted with anti-Flag
antibody, and a band of,75 kDa (arrow) representing Flag-Senataxin is
detected, but only when Flag-L389S-SETX is co-transfected with
C14orf178-GFP. No interaction is detected for Flag-wt-SETX with
C14orf178-GFP. In the lower panel, representing ‘Input’, anti-Flag signal
at , 75 kDa (arrow) is detected in lanes 1, 2, 4, and 5, as expected for
HEK293 cells transfected with recombinant Flag-tagged senataxin
protein, prior to anti-GFP IP. In the upper panel, a non-specific band
of variable intensity (arrowhead) is detected by anti-Flag antibody in
the GFP immunoprecipitates, and is not Flag-senataxin, as it is present
in HEK293 cells not expressing Flag-tagged senataxin, and likely
corresponds to IgG heavy chain.
doi:10.1371/journal.pone.0078837.g006
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Conclusions
In summary, our study of the senataxin interactome revealed a
number of novel aspects of senataxin biology. We report for the
first time strong evidence for senataxin self-association and for
ubiquitin-SUMO post-translational modification of senataxin,
potentially through a set of modifying enzymes and factors from
these pathways. For most of the interactions that we detected, both
wild type and ALS4 L389S senataxin engaged in these protein
interactions. As numerous recent reports have uncovered crucial
roles for mammalian senataxin, including the regulation of
circadian rhythm and microRNA production from the micropro-
cessor complex, our findings could further advance the under-
standing of the role of senataxin in these important processes [54–
56]. Whether mutations in senataxin, such as the L389S alteration,
lead to ALS4 motor neuron degeneration by affecting senataxin
function in these processes, or promote disease pathogenesis by
engaging in an entirely novel and unexpected set of interactions
with small peptide products generated from the transcription of
primate-specific repetitive elements will be the focus of future
studies.
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